96 related articles for article (PubMed ID: 1649695)
21. Serpin inhibitors of urokinase and thrombin in normal rat brain and the 9L brain tumor: evidence for elevated expression of protease nexin I-like inhibitor and a novel sodium dodecyl sulfate-activated tumor antithrombin.
Rao JS; Baker JB; Morantz RA; Kimler B; Evans R; Festoff BW
Cancer Res; 1990 Aug; 50(16):5039-44. PubMed ID: 2116223
[TBL] [Abstract][Full Text] [Related]
22. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
[TBL] [Abstract][Full Text] [Related]
23. Antibodies to the Epstein-Barr virus transactivator protein (ZEBRA) as a valuable biomarker in young patients with nasopharyngeal carcinoma.
Dardari R; Khyatti M; Benider A; Jouhadi H; Kahlain A; Cochet C; Mansouri A; El Gueddari B; Benslimane A; Joab I
Int J Cancer; 2000 Apr; 86(1):71-5. PubMed ID: 10728597
[TBL] [Abstract][Full Text] [Related]
24. Urokinase-type and tissue-type plasminogen activators are essential for in vitro invasion of human melanoma cells.
Meissauer A; Kramer MD; Hofmann M; Erkell LJ; Jacob E; Schirrmacher V; Brunner G
Exp Cell Res; 1991 Feb; 192(2):453-9. PubMed ID: 1899072
[TBL] [Abstract][Full Text] [Related]
25. Increased incidence of IgA antibodies to the Epstein-Barr virus-associated viral capsid antigen and early antigens in patients with chronic lymphocytic leukemia.
Dölken G; Bross KJ; Hecht T; Brugger W; Löhr GW; Hirsch FW
Int J Cancer; 1986 Jul; 38(1):55-9. PubMed ID: 3013785
[TBL] [Abstract][Full Text] [Related]
26. Serological follow-up study on the antibody levels to Epstein-Barr virus-determined nuclear antigen (EBNA) patients with nasopharyngeal carcinoma (NPC) after radiation therapy.
Shimakage M; Ikegami N; Chatani M; Yoshino K; Sato T
Biken J; 1987 Jun; 30(2):45-51. PubMed ID: 2830879
[TBL] [Abstract][Full Text] [Related]
27. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma.
Henle G; Henle W
Int J Cancer; 1976 Jan; 17(1):1-7. PubMed ID: 175020
[TBL] [Abstract][Full Text] [Related]
28. Plasminogen activator system in pemphigus vulgaris.
Schaefer BM; Jaeger CJ; Kramer MD
Br J Dermatol; 1996 Nov; 135(5):726-32. PubMed ID: 8977672
[TBL] [Abstract][Full Text] [Related]
29. [Interaction of plasminogen activator of urokinase type with human serum].
Vakulina OP; Popkova EV; Isachenkov VA
Vopr Med Khim; 1988; 34(4):32-6. PubMed ID: 3143185
[TBL] [Abstract][Full Text] [Related]
30. Clinical evaluation of EBV serology in American patients with nasopharyngeal carcinoma.
Pearson GR; Coates HL; Neel HB; Levine P; Ablashi D; Easton J
IARC Sci Publ (1971); 1978; (20):439-48. PubMed ID: 215526
[TBL] [Abstract][Full Text] [Related]
31. Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase.
Tissot JD; Schneider P; Hauert J; Ruegg M; Kruithof EK; Bachmann F
J Clin Invest; 1982 Dec; 70(6):1320-3. PubMed ID: 6757269
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
[TBL] [Abstract][Full Text] [Related]
33. Transforming growth factor beta inhibits plasminogen activator (PA) activity and stimulates production of urokinase-type PA, PA inhibitor-1 mRNA, and protein in rat osteoblast-like cells.
Allan EH; Zeheb R; Gelehrter TD; Heaton JH; Fukumoto S; Yee JA; Martin TJ
J Cell Physiol; 1991 Oct; 149(1):34-43. PubMed ID: 1834680
[TBL] [Abstract][Full Text] [Related]
34. Plasminogen activator system in oral squamous cell carcinoma.
Baker EA; Leaper DJ; Hayter JP; Dickenson AJ
Br J Oral Maxillofac Surg; 2007 Dec; 45(8):623-7. PubMed ID: 17590247
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA/IgA, EA/IgA, Rta/IgG and EBNA1/IgA for nasopharyngeal carcinoma.
Cai YL; Li J; Lu AY; Zheng YM; Zhong WM; Wang W; Gao JQ; Zeng H; Cheng JR; Tang MZ
Asian Pac J Cancer Prev; 2014; 15(5):2001-6. PubMed ID: 24716925
[TBL] [Abstract][Full Text] [Related]
36. The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors.
Sidelmann J; Jespersen J; Kluft C; Gram J
Clin Chim Acta; 1997 May; 261(1):43-56. PubMed ID: 9187504
[TBL] [Abstract][Full Text] [Related]
37. Localization and diagnostic application of immunodominant domains of the BFRF3-encoded Epstein-Barr virus capsid protein.
van Grunsven WM; Spaan WJ; Middeldorp JM
J Infect Dis; 1994 Jul; 170(1):13-9. PubMed ID: 8014488
[TBL] [Abstract][Full Text] [Related]
38. [The purification and application of Epstein-Barr virus gp125].
Wang G; Pi G; Gu S
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1998 Jun; 12(2):143-6. PubMed ID: 12515193
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
Booth NA; Anderson JA; Bennett B
J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
[TBL] [Abstract][Full Text] [Related]
40. Presence of Epstein-Barr virus specific IgA in saliva of nasopharyngeal carcinoma patients: their activity, origin and possible clinical value.
Desgranges C; de-The G
IARC Sci Publ (1971); 1978; (20):459-69. PubMed ID: 215528
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
